Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease

Neuroscience

Volumn 146, Issue 4, 2007, Pages 1571-1580

  Kung, V W S ^a   Hassam, R ^a   Morton, A J ^a   Jones, S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

dopamine D1 receptor; dorsolateral striatum; glutamate; habit formation; NMDA receptor; synaptic plasticity

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE 2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUNTINGTON CHOREA; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTRIC STIMULATION; EXCITATORY AMINO ACID ANTAGONISTS; HUNTINGTON DISEASE; LONG-TERM POTENTIATION; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; QUINOXALINES; TIME FACTORS;

EID: 34249026735     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2007.03.036     Document Type: Article

References (68)

1. Allen P.B., Zachariou V., Svenningsson P., Lepore A.C., Centonze D., Costa C., Rossi S., Bender G., Chen G., Feng J., Snyder G.L., Bernardi G., Nestler E.J., Yan Z., Calabresi P., and Greengard P. Distinct roles for spinophilin and neurabin in dopamine-mediated plasticity. Neuroscience 140 (2006) 897-911
2. Antonini A., Leenders K.L., Spiegel R., Meier D., Vontobel P., Weigell-Weber M., Sanchez-Pernaute R., de Yebenez J.G., Boesiger P., Weindl A., and Maguire R.P. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119 (1996) 2085-2095
3. Arbuthnott G.W., Ingham C.A., and Wickens J.R. Dopamine and synaptic plasticity in the neostriatum. J Anat 196 (2000) 587-596
4. Augood S.J., Faull R.L., and Emson P.C. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 42 (1997) 215-221
5. Barnes T.D., Kubota Y., Hu D., Jin D.Z., and Graybiel A.M. Activity of striatal neurons reflects dynamic encoding and recoding of procedural memories. Nature 437 (2005) 1158-1161
6. Bates G., Harper P., and Jones L. Huntington's disease. 3rd edition (2002), Oxford University Press, Oxford
7. Bibb J.A., Yan Z., Svenningsson P., Snyder G.L., Pieribone V.A., Horiuchi A., Nairn A.C., Messer A., and Greengard P. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A 97 (2000) 6809-6814
8. Brené S., Hall H., Lindefros N., Karlsson P., Halldin C., and Sedvall G. Distribution of messenger RNAs for D1 dopamine receptors and DARPP-32 in striatum and cerebral cortex of the cynomolgus monkey: relationship to D1 dopamine receptors. Neuroscience 67 (1995) 37-48
9. Caille I., Dumartin B., Le Moine C., Bequeret J., and Bloch B. Ontogeny of the D1 dopamine receptor in the rat striatonigral system: an immunohistochemical study. Eur J Neurosci 7 (1995) 714-722
10. Calabresi P., Pisani A., Mercuri N.B., and Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci 19 (1996) 19-24
11. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19 (1999) 3248-3257
12. Centonze D., Grande C., Saulle E., Martin A.B., Gubellini P., Pavon N., Pisani A., Bernardi G., Moratalla R., and Calabresi P. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci 23 (2003) 8506-8512
13. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernandez J., Chandler S.H., Leavitt B.R., Hayden M.R., and Levine M.S. NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66 (2001) 525-539
14. Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., and Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23 (2003) 961-969
15. Cha J.H., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney Jr. J.B., Davies S.W., Bates G.P., and Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc Lond B Biol Sci 354 (1999) 981-989
16. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., and Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A 95 (1998) 6480-6485
17. Charpier S., and Deniau J.M. In vivo activity-dependent plasticity at cortico-striatal connections: evidence for physiological long-term potentiation. Proc Natl Acad Sci U S A 94 (1997) 7036-7040
18. Charpier S., Mahon S., and Deniau J.M. In vivo induction of striatal long-term potentiation by low-frequency stimulation of the cerebral cortex. Neuroscience 91 (1999) 1209-1222
19. Cummings D.M., Milnerwood A.J., Dallérac G.M., Waights V., Brown J.Y., Vatsavayai S.C., Hirst M.C., and Murphy K.P.S.J. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum Mol Genet 15 (2006) 2856-2868
20. Faure A., Haberland U., Conde F., and El Massioui N. Lesion to the nigrostriatal dopamine system disrupts stimulus-response habit formation. J Neurosci 25 (2005) 2771-2780
21. Fino E., Glowinski J., and Venance L. Bidirectional activity-dependent plasticity at corticostriatal synapses. J Neurosci 25 (2005) 11279-11287
22. Gerdeman G.L., Partridge J.G., Lupica C.R., and Lovinger D.M. It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci 26 (2003) 184-192
23. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 15 (1992) 133-139
24. Gerfen C.R. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 23 (2000) S64-S70
25. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma Jr. F.J., and Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
26. Gibson H.E., Reim K., Brose N., Morton A.J., and Jones S. A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. Eur J Neurosci 22 (2005) 1701-1712
27. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 13 (1990) 244-254
28. Graybiel A.M. Network-level neuroplasticity in cortico-basal ganglia pathways. Parkinsonism Relat Disord 10 (2004) 293-296
29. Hickey M.A., Reynolds G.P., and Morton A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J Neurochem 81 (2002) 46-59
30. Jakel R.J., and Maragos W.F. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci 23 (2000) 239-245
31. Jog M.S., Kubota Y., Connolly C.I., Hillegaart V., and Graybiel A.M. Building neural representations of habits. Science 286 (1999) 1745-1749
32. Johnson M.A., Rajan V., Miller C.E., and Wightman R.M. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J Neurochem 97 (2006) 737-746
33. Kasper E.M., Larkman A.U., Lubke J., and Blakemore C. Pyramidal neurons in layer 5 of the rat visual cortex. II. Development of electrophysiological properties. J Comp Neurol 339 (1994) 475-494
34. Kawaguchi Y., Wilson C.J., Augood S.J., and Emson P.C. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci 18 (1995) 527-535
35. Kerr J.N., and Wickens J.R. Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro. J Neurophysiol 85 (2001) 117-124
36. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., and Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 86 (2001) 2667-2677
37. Lafloret G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., and Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 21 (2001) 9112-9123
38. Levine M.S., Cepeda C., Hickey M.A., Fleming S.M., and Chesselet M.F. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci 27 (2004) 691-697
39. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., and Chesselet M.F. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 58 (1999) 515-532
40. Li J.-Y., Plomann M., and Brundin P. Huntington's disease: a synaptopathy?. Trends Mol Med 9 (2003) 414-420
41. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., and Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 19 (1999) 10428-10437
42. Lovinger D.M., Partridge J.G., and Tang K.-C. Plastic control of striatal glutamatergic transmission by ensemble actions of several neurotransmitters and targets for drugs of abuse. Ann N Y Acad Sci 1003 (2003) 226-240
43. Luthi-Carter R., Apostol B.L., Dunah A.W., DeJohn M.M., Farrell L.A., Bates G.P., Young A.B., Standaert D.G., Thompson L.M., and Cha J.H. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiol Dis 14 (2003) 624-636
44. Mahon S., Deniau J.M., and Charpier S. Corticostriatal plasticity: life after the depression. Trends Neurosci 27 (2004) 460-467
45. Malenka R.C., and Kocsis J.D. Presynaptic actions of carbachol and adenosine on corticostriatal synaptic transmission studied in vitro. J Neurosci 8 (1988) 3750-3756
46. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
47. Morton A.J., and Edwardson J.M. Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J Neurochem 76 (2001) 166-172
48. Murphy K.P.S.J., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 20 (2000) 5115-5123
49. Packard M.G., and Knowlton B.J. Learning and memory functions of the basal ganglia. Annu Rev Neurosci 25 (2002) 563-593
50. Partridge J.G., Tang K.C., and Lovinger D.M. Regional and postnatal heterogeneity of activity-dependent long-term changes in synaptic efficacy in the dorsal striatum. J Neurophysiol 84 (2000) 1422-1429
51. Picconi B., Passino E., Sgobio C., Bonsi P., Barone I., Ghiglieri V., Pisani A., Bernardi G., Ammassari-Teule M., and Calabresi P. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis 22 (2006) 143-152
52. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court J.A., Jaros E., Costa D., Perry R.H., and Perry E.K. Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not D3 receptor binding or dopamine. Neuroscience 90 (1999) 433-445
53. Reisine T.D., Fields J.Z., Stern L.Z., Johnson P.C., Bird E.D., and Yamamura H.I. Alterations in dopaminergic receptors in Huntington's disease. Life Sci 21 (1977) 1123-1128
54. Reynolds G.P., Dalton C.F., Tillery C.L., Mangiarini L., Davies S.W., and Bates G.P. Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. J Neurochem 72 (1999) 1773-1776
55. Reynolds J.N., Hyland B.I., and Wickens J.R. A cellular mechanism of reward-related learning. Nature 413 (2001) 67-70
56. Ronesi J., and Lovinger D.M. Induction of striatal long-term synaptic depression by moderate frequency activation of cortical afferents in rat. J Physiol 562 (2005) 245-256
57. Schultz W. Getting formal with dopamine and reward. Neuron 36 (2002) 241-263
58. Schultz W., Tremblay L., and Hollerman J.R. Changes in behavior-related neuronal activity in the striatum during learning. Trends Neurosci 26 (2003) 321-328
59. Smith A.D., and Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 13 (1990) 259-265
60. Smith R., Chung H., Rundquist S., Maat-Schieman M.L., Colgan L., Englund E., Liu Y.J., Roos R.A., Faull R.L., Brundin P., and Li J.Y. Cholinergic neuronal defect without cell loss in Huntington's disease. Hum Mol Genet 15 (2006) 3119-3131
61. Smith-Roe S.L., and Kelley A.E. Coincident activation of NMDA and dopamine D1 receptors within the nucleus accumbens core is required for appetitive instrumental learning. J Neurosci 20 (2000) 7737-7742
62. Spencer J.P., and Murphy K.P.S.J. Bi-directional changes in synaptic plasticity induced at corticostriatal synapses in vitro. Exp Brain Res 135 (2000) 497-503
63. Usdin M.T., Shelbourne P.F., Myers R.M., and Madison D.V. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum Mol Genet 8 (1999) 839-846
64. Wang Z., Kai L., Day M., Ronesi J., Yin H.H., Ding J., Tkatch T., Lovinger D.M., and Surmeier D.J. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 50 (2006) 443-452
65. Wickens J.R., Reynolds J.N., and Hyland B.I. Neural mechanisms of reward-related motor learning. Curr Opin Neurobiol 13 (2003) 685-690
66. Wise R.A. Dopamine, learning and motivation. Nat Rev Neurosci 5 (2004) 483-494
67. Yin H.H., and Knowlton B.J. The role of the basal ganglia in habit formation. Nat Rev Neurosci 7 (2006) 464-476
68. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., and Raymond L.A. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860